Boreal Genomics specializes in developing advanced linked molecule chemistries designed for high accuracy sequencing and targeted ligation of unknown gene fusions. Operating in the biotechnology sector, Boreal Genomics serves research laboratories and clinical diagnostic centers that require precise genomic analysis. The company’s core product, Linked Target Capture, combines the best of hybridization capture and multiplexed PCR into a streamlined, single-day workflow. This technology is particularly effective for analyzing cell-free DNA, FFPE samples, and genomic DNA. Boreal Genomics generates revenue through the sale of its linked molecule chemistries and associated services, including an Early Access Program that allows labs to trial their innovative panels. The company’s business model focuses on providing cutting-edge genomic solutions that enhance the accuracy and efficiency of genetic research and diagnostics.

Keywords: linked molecule chemistries, high accuracy sequencing, gene fusion analysis, genomic DNA, cell-free DNA, FFPE samples, hybridization capture, multiplexed PCR, biotechnology, clinical diagnostics.